61 results about "Donors organ" patented technology

A method of preserving, storing and transplanting mammalian donor organs. The method includes the cooling of refrigeration preservation, loading pre-freezer preservation, cryopreservation and washing solutions at least containing polyvinylpyrrolidone, a calcium channel blocker, a nucleoside, potassium chloride, polyethylene glycol, at least one amino acid, and a steroid to a temperature of 2° to 4° C. and / or of 0° to 2° C., harvesting a donor organ, perfusing it with one or more of the solution, immersing it in one or more of the solutions and storing it at a temperature above 0° C. or at a temperatures below 0° C. The cryopreservation solution also contains cryopreservative agents. Preserved organs may be transplanted directly from refrigeration storage or from freezer storage by cooling the washing refrigeration preservation solutions to 2° to 4° C., perfusing the organ with washing solution and then preservation solution, and transplanting it.

The present invention provides for cellular compositions which facilitate engraftment of hematopoietic stem cells from a syngeneic, allogeneic or xenogeneic donor. The cellular compositions of the invention facilitate engraftment while minimizing the risk of graft versus host disease in the graft recipient. According to a preferred embodiment of the invention, a cell composition is provided, which cell composition comprises hematopoietic stem cells, such as CD34+ cells and / or facilitating cells, in combination with αβ TCR+ T cells. The invention also relates to methods of using the cellular compositions of the invention to induce donor specific tolerance in a recipient, thus allowing the transplantation of donor organs, cells and tissues. Also disclosed are methods of treating leukemia and cancer as well as infectious diseases caused by viruses.

The current invention provides a new organ preservation solution, suitable for machine perfusion, for maintaining viability of organs, parts of organs and tissues. This solution has been designed to overcome a number of problems associated with hypothermic machine perfusion of donor organs, in particular organs obtained from non-heart-beating donors. The solution prevents or minimizes the adverse affects caused by ischemia, hypoxia, energy and nutrient depletion, acidification, hypothermia and reperfusion injury. The preservation solutions according to the current invention are superior to current state of the art preservation solutions, in particular for preservation and perfusion of organs obtained from non-heart-bearing donors, by supplying increased concentrations and an optimized balance of amino acids, vitamins, anti-oxidants, high molecular weight additives and enhanced buffering capacity. In addition, the preservation solution according to the invention combines optimal physical and chemical properties with the use of readily available, inexpensive and pharmaceutically tested and acceptable compounds, reducing the cost of manufacturing and facilitating medical certification of solutions according to the current invention.

For post-mortem prolongation of the viability of an organ (7, 8, 50, 51) in a donor body, a flow of a solution is introduced from outside the body between a pair of barriers (21, 22) and a return flow including previously introduced quantities of the solution is led to the outside of the body. During a flushing phase, the flow including blood flushed out of the organ (7, 8, 50, 51) is discharged to a drain. Subsequently during a recirculation phase, solution returned from the body is cooled and / or oxygenated and recirculated from outside the body back into the body between the barriers. A system for carrying out the method is also described.

A donor organ treatment apparatus has a container for holding an organ and a perfusion liquid circuit. The perfusion circuit includes a supply conduit downstream of an oxygenator and a heat exchanger for supplying perfusion liquid from the oxygenator and the heat exchanger to an organ in the container and a return conduit upstream of the oxygenator and the heat exchanger for guiding perfusion liquid from the organ inside the container to the oxygenator and the heat exchanger. The supply conduit is provided with an outlet port coupling for connection to a perfusion catheter and the return conduit is provided with an inlet port coupling for connection to a return catheter. A method for successively perfusing an organ in-situ and ex-vivo with liquid circulating through the same perfusion circuit is also described.

The present invention provides methods of preserving, storing and transplanting mammalian donor organs. The method includes the cooling of refrigeration preservation, loading pre-freezer preservation, cryopreservation, and washing solutions at least containing polyvinylpyrrolidone, a calcium channel blocker, a nucleoside, potassium chloride, polyethylene glycol, at least one amino acid, and a steroid to a temperature of 2° to 4° C. and / or of 0° to 2° C., harvesting a donor organ, perfusing it with one or more of the solution, immersing it in one or more of the solutions and storing it at a temperature above 0° C. or at a temperatures below 0° C. including −20° C., −80° C. and −196° C. The cryopreservation solution also contains cryopreservative agents. Preserved organs may be transplanted directly from refrigeration storage or from freezer storage by cooling the washing refrigeration preservation solutions to 2° to 4° C., perfusing the organ with washing solution and then preservation solution, and transplanting it.

A novel and effective strategy for organ transplantation is provided. A therapeutic agent and method for preventing an acute rejection in a transplanted organ and improving prognosis are provided. A therapeutic agent for suppressing a rejection in organ transplantation, which comprises an NF-κB decoy compound, is provided. Representatively, the organ transplantation is kidney transplantation. The therapeutic agent further comprises an ultrasonic inspection contrast agent. A therapeutic agent for improving prognosis in organ transplantation is also provided. The therapeutic agent is administered into a donor organ. The transfection efficiency of the NF-κB decoy compound into the organ may be enhanced by ultrasound treatment.

In human-human transplants, the organ recipient's serum is tested against a broad array of HLA (human leukocyte antigens) alleles. The current clinical assay almost performs a virtual crossmatch which allows elimination of incompatible donor organs in advance, but the current assay presents fragments of HLA polypeptides that are not normally visible to antibodies. As a result, the assay yields false positives. Further the current clinical assay is optimized for human to human transplant, not swine to human transplant. Some HLA antibodies also bind swine leukocyte antigens (SLA). Rather than using beads to present antigens, the compositions and methods provide cellular presentation of potential antigens. The application provides a modified human C1R cell line with significantly reduced antigenicity to human sera. Multiple cell lines, each expressing a different SLA, were created. The modified C1R line may express HLAs or other potential antigens of interest. The application also provides modified HEK293T cells for antigen display.

Human pre-formed xenoantibodies play an important role in the hyperacute rejection response in human xenotransplantation. Disclosed are materials and methods for removing or neutralizing such antibodies. Also disclosed are materials and methods for reducing or eliminating the epitopes in the donor organs that are recognized by such antibodies. Such epitopes are formed as the result of activity by the enzyme α-1,3 galactosyltransferase. The porcine gene encoding α-1,3 galactosyltransferase is disclosed, as are materials and methods for inactivating (“knocking out”) the α-1,3 galactosyltransferase gene in mammalian cells and embryos. Included are nucleic acid constructs useful for inactivating the α-1,3 galactosyltransferase gene in a target cell. Also disclosed is a novel leukemia inhibitory factor (T-LIF) that is useful for maintenance of embryonic stem cells and primordial germ cells in culture.

Apparatus and methods for providing extracorporeal blood circulation and oxygenation control include multi-stage de-airing of blood to provide automated cardiopulmonary replacement to preserve the viability or one or more organs in a clinically dead organ donor or harvested donor organ for subsequent transplantation to an organ receiver patient.

The invention provides a perfusion stock composition, for preserving a donor organ for transplantation, comprising: a source of 60 to 100 mM Na+; a source of 10 to 20 mM K+; a source of 5 to 10 mM Mg2−; a source of 0.25 to 0.75 mM Ca2+; 10 to 40 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris or THAM), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 3-(N-morpholino)propanesulfonic acid (MOPS), 2-(N-morpholino)ethanesulfonic acid (MES), N, / N-bis-(2-hydroxyethyl)-2-aminoethansulfonic acid (BES), or N / -tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid (TES); a source of 10 to 30 mM HCO3−; 1 to 30 mM glucose; 1 to 20 U / L insulin; 1 to 10 mM fructose diphosphate or a salt thereof; 1 to 40 mM aspartate or glutamate; 1 to 10 mM adenosine, cAMP or cGMP; 1 to 10 mM reduced glutathione; and 30 to 100 mM lactobionate or mannitol; and optionally a diluent. The invention also provides a perfusion composition, a kit, a method, and a perfusion apparatus, each related to the perfusion stock composition.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.

The invention provides means and methods for inhibiting T-cell mediated rejection of a xenotransplanted organ by blocking the delivery of co-stimulatory signal 2 (the B7 / CD28 interaction) in order to prevent the activation of xenoreactive T-cells in the recipient. In a first aspect, co-stimulation is prevented by administration to the organ recipient of a soluble form of CTLA-4 from the xenogeneic donor organism. This preferentially binds B7 on the xenograft and blocks the interaction between B7 on the xenogeneic donor cells and CD28 on recipient T-cells. In a second aspect, co-stimulation is antagonized by expressing a ligand for CTLA-4 on the xenogeneic donor cells. This ligand binds to CTLA-4 on activated T-cells of the recipient and antagonizes signal 2. In a third aspect, co-stimulation is prevented by expressing recipient organism MHC class II on the surface of the cells of the xenogeneic donor organ. The donor cells are thus able to present xenoantigens to a recipient T-cell in the context of self-MHC class II. If the donor cells do not express B7, or if B7 is blocked, the xenoreactive recipient T-cell becomes anergic.

A method for treating conditions related to lack of blood supply with a lipid based resuscitation fluid is disclosed. The resuscitation fluid contains a lipid component and an aqueous carrier. The lipid component forms an emulsion with the aqueous carrier. The resuscitation fluid can be used to increase the blood pressure and to carry oxygen to tissues. The resuscitation fluid can also be used for preserving the biological integrity of donor organs for transplantation.

An apparatus to oxygenate and perfuse a bodily tissue for extracorporeal preservation of the bodily tissue. The apparatus may be used to transport donor organs for transplant. The apparatus includes a pneumatic system, a pumping chamber, and an organ chamber. The pneumatic system is configured for the controlled delivery of fluid to and from the pumping chamber based on a predetermined control scheme. The pumping chamber is configured to diffuse a gas into a perfusate and to generate a pulse wave for moving the perfusate through a bodily tissue. The pumping chamber is configured to substantially automatically purge excess fluid from the pumping chamber to an area external to the apparatus.

The invention provides methods, delivery devices, and compositions for topically oxygenating hypoxic tissue with a hemoglobin-based oxygen earner (HBOC), such as Oxyglobin (Oxyb) in order to promote wound healing and / or reducing hypoxia in post-harvest transplant tissue. The invention can be used, among other things, to stimulate angiogenesis and blood flow at a wound site, reduce wound dilation, and promote wound contraction, thereby increasing the overall rate of wound healing. The invention can also be used, among other things, to reduce oxidative stress in pre-implantation donor organ tissue, as well as stimulate the proliferation of granulation tissue, vessel growth, and promote epithelial healing in transplant tissue once it has been implanted.

For post-mortem prolongation of the viability of an organ (7, 8, 50, 51) in a donor body, a flow of a solution is introduced from outside the body between a pair of barriers (21, 22) and a return flow including previously introduced quantities of the solution is led to the outside of the body. During a flushing phase, the flow including blood flushed out of the organ (7, 8, 50, 51) is discharged to a drain. Subsequently during a recirculation phase, solution returned from the body is cooled and / or oxygenated and recirculated from outside the body back into the body between the barriers. A system for carrying out the method is also described.

The present invention relates to the field of organ transplantation. More specifically, the present invention provides methods for predicting organ function after transplantation. In certain embodiments, the method comprises measuring mitochondrial membrane potential from a biopsy sample from the donor organ. The present invention is also applicable to organ dysfunction in general. More specifically, the methods of the present invention may be useful in formulating prognoses for patients with acute or chronic organ dysfunction due to ischemia, infection, drug injury or age. In this rapid procedure, only small samples of tissue are required, enabling the clinical application of mitochondrial function previously thought impractical.

The present invention relates to methods of administering therapeutic agents to a donor organ prior to transplant comprising circulating the therapeutic agent through the donor organ while maintaining the donor organ under ex vivo perfusion conditions, as well as methods of transplanting organs, biologically modifying a donor organ prior to transplant, and treating organ failure using the methods disclosed herein.

The present invention relates to methods for improving the viability and recovery of islets that are separated from a donor organ for subsequent transplantation and more particularly relates to the use of eIF-5A1 siRNAs to enhance the viability of islets.

This invention is directed toward a process for reducing transfusion related complications in a recipient of an allogeneic blood transfusion by adding to the blood to be transfused a photosensitizer comprising riboflavin, irradiating the blood and riboflavin with light, transfusing the irradiated blood into a recipient, and reducing a transfusion related complication by the recipient to cells in the donor blood. The invention is also directed towards a process for preventing rejection of a donor organ by a recipient comprising the steps of transfusing the recipient of the donor organ with treated platelets; and transplanting the donor organ into the recipient.

Provided is a method of treating an immune system disorder not involving T cell proliferation, comprising administering to the animal an immunotoxin comprising a mutant diphtheria toxin moiety linked to an antibody moiety which routes by the anti-CD3 pathway, or derivatives thereof under conditions such that the disorder is treated. Thus, the present method can treat graft-versus-host disease. Also provided is a method of inhibiting a rejection response by inducing immune tolerance in a recipient to a foreign mammalian donor tissue or cells, comprising the steps of: a) exposing the recipient to an immunotoxin so as to reduce the recipients's peripheral blood T-cell lymphocyte population by at least 80%, wherein the immunotoxin is anti-CD3 antibody linked to a diphtheria protein toxin, wherein the protein has a binding site mutation; and b) transplanting the donor cells into the recipient, whereby a rejection response by the recipient to the donor organ cell is inhibited, and the host is tolerized to the donor cell.

The invention discloses a multifunctional organ transplantation working vehicle and an application method thereof. The working vehicle comprises a main vehicle body, wherein a support is arranged below the main vehicle body, an operating platform is arranged at the upper end of the main vehicle body, a thermal-insulation box is arranged at the left half part of the main vehicle body, and an upper end cover of the thermal-insulation box is used as the left half part of the operating platform; a first peristaltic pump and a second peristaltic pump are arranged at the right half part below the operating platform; a lamp arm is arranged on one side of the main vehicle body, and an operation lamp is arranged at the upper end of the lamp arm; a stretcher is arranged below the main vehicle body; and a negative-pressure suction device is also arranged below the operating platform of the main vehicle body. By means of the working vehicle, on the premise that an existing operation vehicle is not required to be transformed, the peripheral space can be fully utilized, cleanliness of an operation area can be guaranteed, and the requirement for accurate regulation of organ perfusion pressure can be met; and meanwhile, smooth obtaining of donor organs and repairing of the organ operating platform for operations are guaranteed, the blank of the lack of professional operating equipment at present is filled up, and a lot of problems during operations are solved.

The invention relates to an isolated organ perfusion pH online monitoring system, which comprises a pH sensor, a pipeline circulation subsystem, buffer solution equipment and a control subsystem. Theinput end of the pipeline circulation subsystem is communicated with the liquid outlet of an isolated organ perfusion system, and the output end of the pipeline circulation subsystem is communicated with the liquid inlet of the isolated organ perfusion system. The buffer solution equipment is used for being communicated with the output end of the pipeline circulation subsystem. The control subsystem is used for driving the pipeline circulation subsystem. The control subsystem is further used for collecting and processing pH data measured by the pH sensor to obtain the pH supplement amount of pH buffer solution and driving the buffer solution equipment to transfer the pH buffer solution to the isolated organ perfusion system based on the pH supplement amount. The pH value of perfusate in the isolated organ perfusion process can be adjusted on line, organ damage caused by slightly acidic perfusate in the isolated organ perfusion process can be prevented, the perfusion effect of isolatedorgans can be improved, and edge donor organs can be saved.

Systems and methods of the invention generally relate to prolonging viability of bodily tissue, especially lung tissue, through the use of an expandable accumulator to maintain a constant pressure within the lumen of the organ even during external pressure fluctuations due to, for example, flight. Systems and methods may include prolonging donor organ viability in storage through the use of an organ container that mimics the geometry and orientation of the organ in vivo.